Announced details
Hard-to-treat cancers; identification of candidate target molecules and elucidation of mechanisms of action for microRNA-based nucleic acid drugs; drug discovery
DDAIF has already been adopted by multiple major pharmaceutical companies and has accumulated a track record of use.
FRONTEO and PURMX Therapeutics have entered into a PoC agreement. FRONTEO will invest in PURMX Therapeutics by subscribing to its third-party allotment of shares.
Headquartered in Minami-ku, Hiroshima; President and CEO: Tahara Eishun (田原栄俊); established in January 2021; a clinical-stage drug-discovery venture originating from Hiroshima University. The company has multiple research and development pipelines for nucleic acid drugs whose active ingredients are unmodified, naturally occurring microRNAs.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Full-text papers from approximately 600 leading journals published by Springer Nature, covering approximately the past 25 years, and projects supported by the Japan Agency for Medical Research and Development, a National Research and Development Agency
| Item | Details |
|---|---|
| Names of Products / Services Covered | Drug Discovery AI Factory（DDAIF）, KIBIT, Nucleic acid drugs whose active ingredients are unmodified, naturally occurring microRNAs, MIRX002 |
| Counterparty | PURMX Therapeutics Co., Ltd. |
| Counterparty overview | Headquartered in Minami-ku, Hiroshima; President and CEO: Tahara Eishun (田原栄俊); established in January 2021; a clinical-stage drug-discovery venture originating from Hiroshima University. The company has multiple research and development pipelines for nucleic acid drugs whose active ingredients are unmodified, naturally occurring microRNAs. |
| Relationship with the Company | FRONTEO and PURMX Therapeutics have entered into a PoC agreement. FRONTEO will invest in PURMX Therapeutics by subscribing to its third-party allotment of shares. |
| Contract Date | 13 August 2026 |
| Launch date | PoC launched on 13 August 2026 (actual) |
| Applicable area | Hard-to-treat cancers; identification of candidate target molecules and elucidation of mechanisms of action for microRNA-based nucleic acid drugs; drug discovery |
| Usage history | DDAIF has already been adopted by multiple major pharmaceutical companies and has accumulated a track record of use. |
| Source | Full-text papers from approximately 600 leading journals published by Springer Nature, covering approximately the past 25 years, and projects supported by the Japan Agency for Medical Research and Development, a National Research and Development Agency |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because microRNA-based nucleic acid drugs involve multiple molecules and signaling pathways, elucidating their mechanisms of action is not easy, and an approach that captures the overall network is required.